Alder BioPharmaceuticals Company Profile (NASDAQ:ALDR)

About Alder BioPharmaceuticals (NASDAQ:ALDR)

Alder BioPharmaceuticals logoAlder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALDR
  • CUSIP: N/A
  • Web: www.alderbio.com
Capitalization:
  • Market Cap: $732.59 million
  • Outstanding Shares: 50,410,000
Average Prices:
  • 50 Day Moving Avg: $14.05
  • 200 Day Moving Avg: $19.12
  • 52 Week Range: $10.05 - $36.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.45
  • P/E Growth: -0.08
Sales & Book Value:
  • Annual Revenue: $112,999.00
  • Price / Sales: 4,751.07
  • Book Value: $5.71 per share
  • Price / Book: 1.87
Profitability:
  • EBIDTA: ($223,700,000.00)
  • Return on Equity: -57.41%
  • Return on Assets: -54.28%
Debt:
  • Current Ratio: 10.47%
  • Quick Ratio: 10.44%
Misc:
  • Average Volume: 1.71 million shs.
  • Beta: 2.57
  • Short Ratio: 5.06
 
Frequently Asked Questions for Alder BioPharmaceuticals (NASDAQ:ALDR)

What is Alder BioPharmaceuticals' stock symbol?

Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder BioPharmaceuticals' earnings last quarter?

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) announced its quarterly earnings data on Thursday, February, 23rd. The company reported ($0.97) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.07. During the same quarter last year, the business posted ($0.60) EPS. View Alder BioPharmaceuticals' Earnings History.

Where is Alder BioPharmaceuticals' stock going? Where will Alder BioPharmaceuticals' stock price be in 2017?

10 equities research analysts have issued 1 year target prices for Alder BioPharmaceuticals' stock. Their predictions range from $17.00 to $51.00. On average, they expect Alder BioPharmaceuticals' share price to reach $39.40 in the next twelve months. View Analyst Ratings for Alder BioPharmaceuticals.

What are analysts saying about Alder BioPharmaceuticals stock?

Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (7/11/2017)
  • 2. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
  • 3. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)

Who are some of Alder BioPharmaceuticals' key competitors?

Who are Alder BioPharmaceuticals' key executives?

Alder BioPharmaceuticals' management team includes the folowing people:

  • Stephen M. Dow, Independent Chairman of the Board
  • Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director
  • Larry K. Benedict, Executive Vice President, Principal Accounting Officer
  • James B. Bucher J.D., Senior Vice President, General Counsel
  • Randal A. Hassler, Senior Vice President - Pharmaceutical Operations
  • John A. Latham Ph.D., Chief Scientific Officer
  • Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary
  • Elisabeth A. Sandoval, Chief Commercial Officer
  • Jeffrey T.L. Smith M.D., Managing Director of Alder BioPharmaceuticals Limited
  • Timothy M. Whitaker M.D., Chief Medical Officer

Who owns Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ING Groep NV (0.66%), Russell Investments Group Ltd. (0.08%), Fox Run Management L.L.C. (0.07%) and Daiwa SB Investments Ltd. (0.02%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.

Who sold Alder BioPharmaceuticals stock? Who is selling Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd.. Company insiders that have sold Alder BioPharmaceuticals stock in the last year include Jeffrey T L Smith, John A Latham, Mark James Litton and Randall C Schatzman. View Insider Buying and Selling for Alder BioPharmaceuticals.

Who bought Alder BioPharmaceuticals stock? Who is buying Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including ING Groep NV, Fox Run Management L.L.C. and Russell Investments Group Ltd.. View Insider Buying and Selling for Alder BioPharmaceuticals.

How do I buy Alder BioPharmaceuticals stock?

Shares of Alder BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alder BioPharmaceuticals' stock price today?

One share of Alder BioPharmaceuticals stock can currently be purchased for approximately $10.65.


MarketBeat Community Rating for Alder BioPharmaceuticals (NASDAQ ALDR)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $39.40 (269.95% upside)

Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Needham & Company LLCSet Price TargetBuy$36.00LowView Rating Details
7/5/2017AegisReiterated RatingBuy$41.00LowView Rating Details
6/28/2017Wells Fargo & CompanyReiterated RatingOutperform$51.00HighView Rating Details
6/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$47.00HighView Rating Details
6/28/2017Credit Suisse GroupDowngradeOutperform -> Neutral$30.00 -> $17.00HighView Rating Details
6/12/2017Leerink SwannReiterated RatingOutperform$32.00MediumView Rating Details
4/17/2017Jefferies Group LLCReiterated RatingBuy$43.00LowView Rating Details
12/9/2016BMO Capital MarketsReiterated RatingOutperform$42.00N/AView Rating Details
9/30/2016Brean CapitalInitiated CoverageBuy$45.00N/AView Rating Details
9/13/2016J P Morgan Chase & CoInitiated CoverageOverweight$40.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Earnings by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Earnings History by Quarter for Alder BioPharmaceuticals (NASDAQ ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($0.95)($1.99)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.90)($0.97)ViewN/AView Earnings Details
10/27/2016Q3($0.85)($0.70)ViewListenView Earnings Details
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.40)ViewListenView Earnings Details
3/4/2015Q414($0.18)($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.22)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/20/2014Q1($0.22)($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
2017 EPS Consensus Estimate: ($3.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.98)($0.86)($0.92)
Q2 20172($1.02)($0.85)($0.94)
Q3 20172($1.02)($0.91)($0.97)
Q4 20172($1.02)($0.99)($1.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Ownership Percentage: 10.60%
Insider Trades by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Trades by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017Stephen M DowDirectorBuy25,000$10.00$250,000.00View SEC Filing  
6/20/2017Jeffrey T L SmithVPSell585$20.00$11,700.00View SEC Filing  
1/18/2017Mark James LittonInsiderSell1,498$23.10$34,603.80View SEC Filing  
1/9/2017Mark James LittonInsiderSell9,516$23.01$218,963.16View SEC Filing  
12/1/2016Jeffrey T. L. SmithVPSell3,000$22.78$68,340.00View SEC Filing  
12/1/2016John A. LathamInsiderSell3,636$22.78$82,828.08View SEC Filing  
11/7/2016Randall C SchatzmanCEOSell10,000$25.16$251,600.00View SEC Filing  
10/17/2016Mark James LittonInsiderSell6,000$27.50$165,000.00View SEC Filing  
10/3/2016Jeffrey T L SmithVPSell3,000$31.14$93,420.00View SEC Filing  
10/3/2016John A LathamInsiderSell10,000$31.32$313,200.00View SEC Filing  
10/3/2016Randall C SchatzmanCEOSell8,181$31.15$254,838.15View SEC Filing  
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.00View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.00View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alder BioPharmaceuticals (NASDAQ:ALDR)
Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
Source:
DateHeadline
finance.yahoo.com logoDELTA DRONE : Six-month report on the liquidity agreement with Louis Capital Markets
finance.yahoo.com - July 24 at 1:26 PM
americanbankingnews.com logoStephen M. Dow Buys 25,000 Shares of Alder BioPharmaceuticals, Inc. (ALDR) Stock
www.americanbankingnews.com - July 18 at 10:29 PM
bizjournals.com logoAlder BioPharmaceuticals nets $162 million to continue migraine drug development
www.bizjournals.com - July 18 at 10:14 PM
finance.yahoo.com logoAlder BioPharmaceuticals Announces Closing of Public Offering of Common Stock
finance.yahoo.com - July 18 at 5:11 PM
thestreet.com logoBiotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta - TheStreet.com
www.thestreet.com - July 17 at 4:02 PM
americanbankingnews.com logoAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - July 17 at 8:20 AM
americanbankingnews.com logoAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 14 at 5:05 PM
streetinsider.com logoAlder BioPharma (ALDR) Prices 15M Share Offering at $10/Sh
www.streetinsider.com - July 14 at 2:32 AM
rttnews.com logoAlder Biopharmaceuticals Inc. (ALDR) Fell To A New Low After Offering
www.rttnews.com - July 14 at 2:32 AM
finance.yahoo.com logoAlder BioPharmaceuticals, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - July 14 at 2:32 AM
finance.yahoo.com logoCramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation
finance.yahoo.com - July 14 at 2:32 AM
fool.com logoHere's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back - Motley Fool
www.fool.com - July 13 at 9:29 PM
finance.yahoo.com logoWhy I say small-cap biotechs are only for speculation
finance.yahoo.com - July 13 at 9:29 PM
finance.yahoo.com logoAlder BioPharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - July 13 at 9:29 PM
nasdaq.com logoPre-Market Most Active for Jul 13, 2017 : YNDX, FOLD, SNAP, MT, ALDR, ARNA, TEF, QAT, DAL, TGT, QQQ, TEVA - Nasdaq
www.nasdaq.com - July 13 at 4:26 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Yandex, US Retailers, Navigator, Alder BioPharma - Nasdaq
www.nasdaq.com - July 13 at 4:25 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc.
finance.yahoo.com - July 13 at 4:25 PM
finance.yahoo.com logoHere's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
finance.yahoo.com - July 13 at 4:25 PM
fool.com logoWhy Alder Biopharmaceuticals Inc Is Sinking Today - Motley Fool
www.fool.com - July 13 at 2:12 AM
globenewswire.com logoAlder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - July 12 at 9:12 PM
finance.yahoo.com logoAlder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
finance.yahoo.com - July 12 at 9:11 PM
benzinga.com logoMid-Morning Market Update: Markets Open Higher; Fastenal Earnings Top Views - Benzinga
www.benzinga.com - July 12 at 4:10 PM
nasdaq.com logoMid-Afternoon Market Update: NASDAQ Up Over 1%; MSC Industrial Shares Plummet - Nasdaq
www.nasdaq.com - July 12 at 4:10 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Ocular Therapeutix, NRG Energy, Alder BioPharma, Cara - Nasdaq
www.nasdaq.com - July 12 at 4:10 PM
finance.yahoo.com logoWednesday’s Biotech Movers: Ibio Inc (IBIO) Rallies, Ocular Therapeutix Inc (OCUL) Tumbles, Alder Biopharmaceuticals Inc (ALDR) Dives
finance.yahoo.com - July 12 at 4:10 PM
rttnews.com logoAlder Biopharmaceuticals Inc. (ALDR) Is Down After Offering Announcement
www.rttnews.com - July 12 at 2:57 AM
americanbankingnews.com logoAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM
globenewswire.com logoAlder BioPharmaceuticals, Inc. Announces Commencement of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - July 11 at 4:55 PM
finance.yahoo.com logoAlder BioPharmaceuticals, Inc. Announces Commencement of Public Offering of Common Stock
finance.yahoo.com - July 11 at 4:55 PM
americanbankingnews.com logoAegis Reiterates Buy Rating for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
www.americanbankingnews.com - July 5 at 9:54 AM
americanbankingnews.com logoFY2018 EPS Estimates for Alder BioPharmaceuticals, Inc. Cut by Leerink Swann (ALDR)
www.americanbankingnews.com - June 30 at 11:53 AM
americanbankingnews.com logoAlder BioPharmaceuticals, Inc. (ALDR) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - June 29 at 11:44 PM
benzinga.com logoAlder Biopharma Plummets After Results Of Eptinezumab 1 Phase Trial - Benzinga
www.benzinga.com - June 28 at 8:56 PM
seekingalpha.com logoAlder's Headache Worsens - Seeking Alpha
seekingalpha.com - June 28 at 8:56 PM
zacks.com logoAlder's Shares Dip Despite Positive Migraine Trial Results
www.zacks.com - June 28 at 3:54 PM
finance.yahoo.com logoAlder Biopharmaceuticals Inc Sell-Off A Buying Opportunity? Needham Weighs In
finance.yahoo.com - June 28 at 3:54 PM
finance.yahoo.com logoAlder's Shares Dip Despite Positive Migraine Trial Results
finance.yahoo.com - June 28 at 3:54 PM
americanbankingnews.com logoWells Fargo & Company Reiterates "Outperform" Rating for Alder BioPharmaceuticals, Inc. (ALDR)
www.americanbankingnews.com - June 28 at 1:50 PM
americanbankingnews.com logoAlder BioPharmaceuticals, Inc. (ALDR) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - June 28 at 1:50 PM
americanbankingnews.com logoAlder BioPharmaceuticals' (ALDR) Overweight Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - June 28 at 12:40 PM
americanbankingnews.com logoAlder BioPharmaceuticals, Inc. (ALDR) Rating Lowered to Neutral at Credit Suisse Group
www.americanbankingnews.com - June 28 at 8:16 AM
benzinga.com logoMid-Day Market Update: Crude Oil Up Over 2%; Xenon Pharmaceuticals Shares Slide - Benzinga
www.benzinga.com - June 27 at 8:34 PM
thestreet.com logoAlder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers - TheStreet.com
www.thestreet.com - June 27 at 8:34 PM
nasdaq.com logoImplied Volatility Surging for Alder Biopharmaceuticals (ALDR) Stock Options - Nasdaq
www.nasdaq.com - June 27 at 8:34 PM
marketwatch.com logoAlder BioPharma stock drops nearly 20% as investors shrug off positive migraine drug results - MarketWatch
www.marketwatch.com - June 27 at 8:34 PM
finance.yahoo.com logoAlder’s flagship migraine drug trial posts strong results — and so does the placebo
finance.yahoo.com - June 27 at 8:34 PM
benzinga.com logoPiper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management
www.benzinga.com - June 27 at 3:32 PM
finance.yahoo.com logoAlder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine
finance.yahoo.com - June 27 at 3:32 PM
finance.yahoo.com logoAlder's migraine drug meets main goal in late-stage study
finance.yahoo.com - June 27 at 3:32 PM
finance.yahoo.com logoImplied Volatility Surging for Alder Biopharmaceuticals (ALDR) Stock Options
finance.yahoo.com - June 27 at 3:32 PM

Social

Chart

Alder BioPharmaceuticals (ALDR) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff